NASDAQ:COLL - Collegium Pharmaceutical Stock Price, News & Analysis

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) posted its earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The specialty pharmaceutical company had revenue of $75.04 million for the quarter, compared to the consensus estimate of $75.77 million. Collegium Pharmaceutical had a negative return on equity of 26.10% and a negative net margin of 7.45%. The business's revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.40) EPS. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Collegium Pharmaceutical.

5 analysts have issued 12-month price targets for Collegium Pharmaceutical's shares. Their predictions range from $22.00 to $33.00. On average, they expect Collegium Pharmaceutical's share price to reach $26.20 in the next twelve months. This suggests a possible upside of 116.0% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

Headlines about COLL stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Collegium Pharmaceutical.

Some companies that are related to Collegium Pharmaceutical include Pacira Biosciences (PCRX), Corcept Therapeutics (CORT), Madrigal Pharmaceuticals (MDGL), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), G1 Therapeutics (GTHX), Turning Point Therapeutics (TPTX), Aimmune Therapeutics (AIMT), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Gossamer Bio (GOSS), Theravance Biopharma (TBPH), BELLUS Health (BLUSF) and AnaptysBio (ANAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), NVIDIA (NVDA), Celgene (CELG), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Synergy Pharmaceuticals (SGYP), GW Pharmaceuticals PLC- (GWPH), Bausch Health Companies (BHC) and Advanced Micro Devices (AMD).

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (12.95%), Janus Henderson Group PLC (12.95%), BlackRock Inc. (7.43%), Vanguard Group Inc. (4.70%), Rice Hall James & Associates LLC (3.78%) and Morgan Stanley (1.53%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan, Paul Brannelly and Scott Dreyer. View Institutional Ownership Trends for Collegium Pharmaceutical.

COLL stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, D. E. Shaw & Co. Inc., A.R.T. Advisors LLC, Morgan Stanley, State Board of Administration of Florida Retirement System, Trexquant Investment LP, Bogle Investment Management L P DE and United Services Automobile Association. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View Insider Buying and Selling for Collegium Pharmaceutical.

COLL stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Janus Henderson Group PLC, Renaissance Technologies LLC, Cortina Asset Management LLC, Nuveen Asset Management LLC, BlackRock Inc., Eversept Partners LP and Bank of Montreal Can. View Insider Buying and Selling for Collegium Pharmaceutical.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $12.13.

Collegium Pharmaceutical has a market capitalization of $406.00 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.